Skip to main content
OpenTrials

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,467 public trials 2,848 recruiting studies
Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Active, not recruiting

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

NCT06924970

Conditions
Anemia, Anemia, Hemolytic, Anemia, Hemolytic, Congenital, +7 more
Locations
  • UConn Health Farmington, Connecticut, United States
  • MedStar Washington Hospital Center Washington D.C., District of Columbia, United States
  • Emory-Children's Center/ Children's Healthcare of Atlanta: Arthur M. Blank Hospital Atlanta, Georgia, United States
  • Henry Ford Health System Detroit, Michigan, United States
View all 20 locations
View Trial Details
Active, not recruiting

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

NCT04515238

Conditions
Chronic Lymphoid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Hamatologische/Onkologische Gemeinschaftspraxis Augsburg, Germany
  • Universitätsklinik Köln Cologne, Germany
  • Onkologische Schwerpunktpraxis Esslingen am Neckar, Germany
  • Evangelische Krankenhaus Hamm Hamm, Germany
View Trial Details
Active, not recruiting

CINC424A2X01B Rollover Protocol

NCT02386800

Conditions
Acute Myeloid Leukemia, Anemia, Anemia, Hemolytic, +31 more
Locations
  • Novartis Investigative Site Darlinghurst, New South Wales, Australia
  • Novartis Investigative Site Herston, Queensland, Australia
  • Novartis Investigative Site Wooloongabba, Queensland, Australia
  • Novartis Investigative Site Bedford Park, South Australia, Australia
View all 97 locations
View Trial Details
Active, not recruiting

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

NCT02879695

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +22 more
Locations
  • Yale University New Haven, Connecticut, United States
  • University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Active, not recruiting

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

NCT02521493

Conditions
Abnormalities, Multiple, Acute Myeloid Leukemia, Bone Marrow Diseases, +21 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 191 locations
View Trial Details
Active, not recruiting

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT02966756

Conditions
Chromosome 17 deletion, Chronic Disease, Chronic Lymphocytic Leukemia (CLL), +16 more
Locations
  • Concord Repatriation General Hospital /ID# 201261 Concord, New South Wales, Australia
  • Anhui Provincial Cancer Hospital /ID# 209458 Hefei, Anhui, China
  • Peking University People's Hospital /ID# 156575 Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital /ID# 156579 Fuzhou, Fujian, China
View all 31 locations
View Trial Details

Related conditions